ESR1 and neoplasm: Although the overall benefit from tamoxifen in reducing the risk of breast cancer relapse is clear, with clinical trials demonstrating an approximate 50% reduction in relapse for patients with ER+ tumours [10], [15], a subset of patients fail to respond to the drug, either due to acquired resistance or to an intrinsic insensitivity to tamoxifen [16].